Acurx Pharmaceuticals Inc
acurxpharma.comWhat Do They Do?
Develops antibiotic candidates for difficult-to-treat bacterial infections, including C. difficile and infections caused by resistant Gram-positive bacteria.
10-K for FY2025, filed Mar 12, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 12, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$2.3MView ↗
- ▲ 0% (Loss)
- vs −$2.2M in Q2 FY2025
Who Do They Compete With?
Competes with Optimer Pharmaceuticals, Cubist Pharmaceuticals, Merck &, Finch Therapeutics, Nestle Health Sciences, Ferring Pharmaceuticals, Crestone, and MGB Biopharma
10-K for FY2025, filed Mar 12, 2026Fidaxomicin (Dificid® in the U.S., Dificlir™ in Europe) is approved for the treatment of CDI in the U.S. and Europe. Fidaxomicin was…View ↗
Loading...
